Drug Profile


Alternative Names: Anti-IL-13 monoclonal antibody - MedImmune; Anti-interleukin-13 monoclonal antibody - MedImmune; CAT-354

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Icahn School of Medicine at Mount Sinai; MedImmune
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Asthma
  • Phase II Alopecia areata; Atopic dermatitis
  • Discontinued Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Ulcerative colitis

Most Recent Events

  • 22 May 2017 LEO Pharma plans the ECZTRA 2 phase III trial for Atopic dermatitis (Monotherapy, Treatment-experienced) in USA (NCT03160885)
  • 10 May 2017 LEO Pharma plans to initiate the phase III ECZTRA 1 trial in Atopic dermatitis (Monotherapy, Treatment-experienced) in USA (SC) (NCT03131648)
  • 22 Mar 2017 MedImmune terminates a phase I trial in Asthma (Treatment-experienced) in United Kingdom due to slow recruitment rate (IV) (NCT00974675)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top